Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Edwards Lifesciences Corporation Issues Q3 2012 Outlook In Line With Estimates; Lowers FY 2012 Revenue Outlook; Reaffirms FY 2012 Net Income Outlook; Raises Low End Of Prior FY 2012 EPS Outlook


Tuesday, 24 Jul 2012 04:01pm EDT 

Edwards Lifesciences Corporation announced that given updated projections and the recent movement in foreign exchange rates, the Company now expect fiscal 2012 sales of $1.90 billion to $1.97 billion, which represents an underlying growth rate of approximately 20%. Excluding special items, the Company now expect diluted earnings per share (EPS) of $2.60 to $2.68, and continue to expect fiscal 2012 net income growth of approximately 30%. For the third quarter 2012, the Company project total sales of $465 million to $485 million, and diluted EPS, excluding special items, to be between $0.57 and $0.61. The Company reported net income of $241 million in fiscal 2011. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $484 million and EPS of $0.65 for third quarter of 2012; revenue of $1.96 billion, net income of $314 million and EPS of $2.66 for fiscal 2012. 

Company Quote

88.15
0.26 +0.30%
4:04pm EDT